Chemed Corp's Net Income Surges 10.8% to $302M on VITAS Hospice Boom
Chemed CorporationDescription
What this story covers
Chemed Corp reported 2024 net income of $302M, up 10.8%, driven by 16.4% VITAS revenue growth to $1.53B amid higher admissions, offsetting Roto-Rooter's 5.2% decline. Adjusted EBITDA rose 11.3% to $503M. Strong cash flow of $417.5M funded $361M buybacks and $85M Covenant acquisition. Risks include Medicare reliance and competition. Outlook: EPS $24.94-25.45.
Story snapshot
CompanyChemed Corporation
TickerCHE
VariantStandard detailed
Duration11:38
Filing type10-K
PeriodAnnual 2024
IndustryHealthcare & Pharmaceuticals
Accession0001562762-25-000038
Full Story Script
Content not available for this story.